Sensitive CAR T cells redefine targetable CD70 expression in solid tumors
Science · 2026
DOI: 10.1126/science.adv7378 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, 2026. Verfasst von Sophie A Hanina und 21 weiteren Autor:innen. Beteiligte Einrichtung: Columbia Initiative in Cell Engineering and Therapy (CICET), Department of Medicine, Columbia University Irving Medical Center, Columbia University, …. Hauptthemen laut MEDLINE: CD27 Ligand, Immunotherapy, Adoptive, Neoplasms, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, U.S. Department of Defense, HEE/NIHR.
Abstract (Originalsprache)
Solid tumor antigen heterogeneity is a major challenge for cancer immunotherapies, including chimeric antigen receptor (CAR) T cells. Unlike CD19 for B cell malignancies, no target with pan-cellular expression in solid tumors and absence in normal vital cells has been identified. CD70 is a promising candidate, physiologically confined to immune cell subsets and aberrantly expressed in many cancers. We show that heterogeneous CD70 expression in tumors is epigenetically regulated, ranging from high to very low in individual cells, appearing negative by conventional detection methods. Using a highly sensitive CD70 receptor, HLA-independent T cell (HIT) receptor coexpressing CD80 and 4-1BBL for costimulation, we efficiently eliminated CD70-heterogeneous tumors that evade prototypic CAR T cells. These findings provide a potential strategy to treat a broad range of solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Columbia Initiative in Cell Engineering and Therapy (CICET), Department of Medicine, Columbia University Irving Medical Center, Columbia University, New York, NY USA.
- Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Orthopedic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Antitumor Assessment Core Facility, Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Bio-Imaging Resource Center, The Rockefeller University, New York, NY USA.
ORCID-Profile: Sophie A Hanina, Tyler Park, Vinagolu K Rajasekhar, Jorge Mansilla-Soto, Sascha Haubner, Huiyong Zhao, Sarah Nataraj, Priyam Banerjee, Richard Koche, Pierre-Jacques Hamard, Zeynep C Tarcan, Dmitriy Zamarin, John H Healey, Elisa de Stanchina, Robert J Motzer, Ritesh R Kotecha, Christina S Leslie, Michel Sadelain
Förderung
- NCI NIH HHS
- U.S. Department of Defense
- HEE/NIHR
Zitieren
APA
Hanina, S. A., Park, T., Lopez, M., Rajasekhar, V. K., Mansilla-Soto, J., Haubner, S., Zhao, H., Kogel, F., Nataraj, S., Banerjee, P., Koche, R., Hamard, P. J., Tarcan, Z. C., Chi, D. S., Zamarin, D., Healey, J. H., de Stanchina, E., Motzer, R. J., Kotecha, R. R., …, & Sadelain, M. (2026). Sensitive CAR T cells redefine targetable CD70 expression in solid tumors. Science. https://doi.org/10.1126/science.adv7378
Vancouver
Hanina SA, Park T, Lopez M, Rajasekhar VK, Mansilla-Soto J, Haubner S, et al. Sensitive CAR T cells redefine targetable CD70 expression in solid tumors. Science. 2026. doi:10.1126/science.adv7378
BibTeX
@article{Hanina2026,
author = {Hanina, Sophie A and Park, Tyler and Lopez, Michael and Rajasekhar, Vinagolu K and Mansilla-Soto, Jorge and Haubner, Sascha and Zhao, Huiyong and Kogel, Friederike and Nataraj, Sarah and Banerjee, Priyam and Koche, Richard and Hamard, Pierre-Jacques and Tarcan, Zeynep C and Chi, Dennis S and Zamarin, Dmitriy and Healey, John H and de Stanchina, Elisa and Motzer, Robert J and Kotecha, Ritesh R and Hakimi, A Ari and Leslie, Christina S and Sadelain, Michel},
title = {Sensitive CAR T cells redefine targetable CD70 expression in solid tumors},
journal = {Science},
year = {2026},
doi = {10.1126/science.adv7378}
}
EUVIMED